Which of the following medications is a Protease Inhibitor (HIV)?

Which of the following medications is a Protease Inhibitor (HIV)?

• A. Elvitegravir
• B. Bictegravir
• C. Prezista (Darunavir)
• D. Raltegravir

Answer: (C)

A Protease Inhibitor is a class of antiviral drug that blocks the activity of the protease enzyme, which is essential for HIV replication. The correct answer is Prezista (Darunavir), as it is specifically classified as a Protease Inhibitor used in the treatment of HIV. Darunavir works by preventing the HIV virus from maturing and becoming infectious, thus it is effective in controlling the viral load in patients. It's important to highlight that while other options, such as Elvitegravir, Bictegravir, and Raltegravir, are also utilized in the treatment of HIV, they belong to different classes of antiretroviral medications. Elvitegravir and Bictegravir are Integrase Strand Transfer Inhibitors, while Raltegravir is also an Integrase Inhibitor. Their mechanisms of action differ significantly from that of Protease Inhibitors, focusing on interrupting the viral replication process at different stages. Understanding the classification and function of these drugs is vital for selecting appropriate antiretroviral therapy for HIV patients.

A Protease Inhibitor is a class of antiviral drug that blocks the activity of the protease enzyme, which is essential for HIV replication. The correct answer is Prezista (Darunavir), as it is specifically classified as a Protease Inhibitor used in the treatment of HIV.

Darunavir works by preventing the HIV virus from maturing and becoming infectious, thus it is effective in controlling the viral load in patients. It's important to highlight that while other options, such as Elvitegravir, Bictegravir, and Raltegravir, are also utilized in the treatment of HIV, they belong to different classes of antiretroviral medications. Elvitegravir and Bictegravir are Integrase Strand Transfer Inhibitors, while Raltegravir is also an Integrase Inhibitor. Their mechanisms of action differ significantly from that of Protease Inhibitors, focusing on interrupting the viral replication process at different stages.

Understanding the classification and function of these drugs is vital for selecting appropriate antiretroviral therapy for HIV patients.